Product Options. Where specification paragraphs or subparagraphs titled “Product Options” indicate that size, profiles, and dimensional requirements on drawings are based on a specific product or system, provide either the specific product or system indicated, or a comparable product or system by one of the other named manufacturers. As stated in Subparagraph 4.c above, products must be approved by the substitution process set forth in Section 13.06 below in order to be deemed “comparable.”
Product Options. For each Product sold by Diomed beginning on the Effective Date and ending November 15, 2005, Diomed will grant to the LP under the Plan an option (a "Product Option") to purchase five (5) shares of Common Stock of Diomed up to an aggregate maximum of 45,000 shares (which number is inclusive of shares subject to options granted under Section 3.5). The Product Options shall be granted as of the end of each calendar quarter in which Product sales were sold (subject to adjustment for returns and uncollected accounts) and shall be fully vested on grant. The Product Options issued hereunder shall be subject to the same terms as the Initial Options issued under Section 3.5 except that the exercise price of each quarterly grant shall be based on fair market value of Diomed common stock at the time of grant as determined at the sole discretion of the Board of Director and consistent with other Employee options (if any) granted during the quarter.
Product Options. 4.1.1 ChemoCentryx hereby grants to GSK the exclusive right, exercisable at GSK’s sole discretion, to elect to obtain exclusive worldwide rights to continue to develop and commercialize at least four (4) and no more than six (6) Option Compounds (and their associated Back-up Compounds) as set forth below in Section 4.3, as Product Candidates and into Licensed Products under the terms and conditions set forth in this Agreement (each such right to elect, a “Product Option”). Each such Option Compound together with its associated Backup Compounds are collectively referred to as one set of Progressed Compounds, all of which are included within and subject to a single Product Option exercise. For clarity, the exercise by GSK *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. of a Product Option with respect to a given set of Progressed Compounds shall be specific to that particular set of Progressed Compounds only and results in the grant to GSK of the exclusive, worldwide and sublicenseable right and license to Develop and commercialize any Product Candidates or Licensed Products based upon or which incorporate any of such Progressed Compounds. Any additional Collaboration Compounds that are developed subsequently (or in tandem) by ChemoCentryx against the same Collaboration Target (other than the associated Backup Compounds to a given Option Compound) and which progress to become an Option Compound shall be the subject of a separate and distinct Product Option and exercise of the same by GSK.
Product Options. A. Provide products that comply with the Contract Documents, are undamaged, and are new at the time of installation.
Product Options. With effect from the Effective Date, Autolus hereby grants to BioNTech, on an Option Product-by-Option Product basis, the exclusive option to obtain the exclusive right to co-fund certain development costs in respect of the relevant Option Product in return for a [***] profit sharing arrangement, and to obtain the exclusive option to co-promote and co-commercialize the Option Product, in each case, for all oncology Indications and subject to and as further set out in this Article 4 and Schedule 4.4(a) (each, a “Product Option”).
Product Options. A. For products specified by naming several “comparable” products or manufacturers, one of the products or manufacturers named may be selected. Where the phrases “No substitutions” or “Substitutions” or similar connotations do not appear, no other manufactures or products will be considered.
Product Options. A. General Product Requirements: Provide products that comply with the Contract Documents, that are undamaged and, unless otherwise indicated, that are new at time of installation.
Product Options. 27 4.1 Product Options. 27 4.2 Provision of Data. 28 4.3 Development Plan. 29 4.4 Negotiation of Product Agreement 29 4.5 Option Exercise. 29 4.6 Failure to Exercise Option or Rejection of Baseball Arbitration. 30
Product Options. 4.1.1 ChemoCentryx hereby grants to GSK the exclusive right, exercisable at GSK’s sole discretion, to elect to obtain exclusive worldwide rights to continue to develop and commercialize at least four (4) and no more than six (6) Option Compounds (and their associated Back-up Compounds) as set forth below in Section 4.3, as Product Candidates and into Licensed Products under the terms and conditions set forth in this Agreement (each such right to elect, a “Product Option”). Each such Option Compound together with its associated Backup Compounds are collectively referred to as one set of Progressed Compounds, all of which are included within and subject to a single Product Option exercise. For clarity, the exercise by GSK of a Product Option with respect to a given set of Progressed Compounds shall be specific to that particular set of Progressed Compounds only and results in the grant to GSK of the exclusive, worldwide and sublicenseable right and license to Develop and commercialize any Product Candidates or Licensed Products based upon or which incorporate any of such Progressed Compounds. Any additional Collaboration Compounds that are developed subsequently (or in tandem) by ChemoCentryx against the same Collaboration Target (other than the associated Backup Compounds to a given Option Compound) and which progress to become an Option Compound shall be the subject of a separate and distinct Product Option and exercise of the same by GSK.
Product Options. For each EVLT Laser (as defined in the Purchase Agreement) sold by Diomed beginning on the Effective Date and ending November 15, 2005, Diomed will grant to the LLC under the Plan an option (a "Product Option") to purchase twenty five (25) shares of Common Stock of Diomed up to an aggregate maximum of 180,000 shares (which number is inclusive of shares subject to options granted under the 2001 Agreement). For purposes of the foregoing, EVLT Lasers shall be considered "sold" on the date when Diomed has received payment in full for such EVLT Lasers. The Product Options shall be granted as of the end of each calendar quarter in which EVLT Lasers were sold (subject to adjustment for returns and uncollected accounts) and shall be fully vested on grant. The Product Options issued hereunder shall be subject to the same terms as the Product Options issued under Section 3.6 of the 2001 Agreement.
